Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-NK Therapy in Relapsed/Refractory Multiple Myeloma
NCT05008536Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple myeloma (MM), sponsored by Xinqiao Hospital. Primary endpoints: Overall Remission Rate at 2 months and Incidence of Dose Limiting Toxicity at 2 months. Status: unknown.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05008536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008536.